Clinical Trials Browser

Withdrawn × OTHER × bexmarilimab × Clear all

NCT05171062 2023-07-20

Dose Escalation Trial of Bexmarilimab (FP-1305) Plus Pembrolizumab in Non-Small Cell Lung Cancer

Phase 1 Withdrawn

Carcinoma, Non-Small-Cell Lung